Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is NutriSystem the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if NutriSystem (Nasdaq: NTRI  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at NutriSystem.


What We Want to See


Pass or Fail?

Growth 5-Year Annual Revenue Growth > 15% 8.5% Fail
  1-Year Revenue Growth > 12% (7.3%) Fail
Margins Gross Margin > 35% 55.2% Pass
  Net Margin > 15% 5.3% Fail
Balance Sheet Debt to Equity < 50% 43.1% Pass
  Current Ratio > 1.3 2.44 Pass
Opportunities Return on Equity > 15% 25.7% Pass
Valuation Normalized P/E < 20 15.84 Pass
Dividends Current Yield > 2% 4.6% Pass
  5-Year Dividend Growth > 10% 0%* Fail
  Total Score   6 out of 10

Source: Capital IQ, a division of Standard and Poor's. *Growth rate since NutriSystem started paying a dividend in May 2008. Total score = number of passes.

With six points, NutriSystem is helping investors with their risk reduction programs. The weight-loss company is at the heart of people's perennial efforts to improve themselves, but lately, business has slimmed down almost as much the waistlines of the company's customers.

NutriSystem is well known for its home delivery of prepackaged meals designed to help people lose weight. That food is a key distinction between NutriSystem and competitors Weight Watchers International (NYSE: WTW  ) and Medifast (NYSE: MED  ) . But it can also prove a liability for the company: because NutriSystem clients are so dependent on prepared meals, many have trouble maintaining weight loss when they try to move back to cooking their own food.

Lately, NutriSystem has had trouble bulking up its finances. In its most recent quarter, the company reversed a year-ago profit with a loss of $3.4 million, and sales fell more than 16%. Short sellers are piling up against the stock, with more than a quarter of available shares sold short as of late June.

Another constant threat is competition from a new diet drug. Last year, the FDA rejected both Arena Pharmaceuticals' (Nasdaq: ARNA  ) lorcaserin and VIVUS' (Nasdaq: VVUS  ) Qnexa. And although Orexigen (Nasdaq: OREX  ) managed to get a recommendation from an FDA advisory panel, the full FDA still chose to require a more extensive trial before it would consider approving its Contrave drug. Still, it's probably only a matter of time before some obesity drug goes on the market, and when that happens, it could spell big trouble for NutriSystem.

Despite its strong score and impressive dividend yield , NutriSystem faces plenty of uncertainty in its future. Unless it can manage to demonstrate its dominance over its peers in some unexpected way, NutriSystem isn't likely to craft itself into a perfect stock.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

Click here to add NutriSystem to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Finding the perfect stock is only one piece of a successful investment strategy. Get the big picture by taking a look at our "13 Steps to Investing Foolishly."

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.

Read/Post Comments (2) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On July 17, 2011, at 1:15 PM, paulcmurray wrote:

    Perfect Stock? The title sure seems tempting. But Nutrisystems hardly seems a candidate to review. If the candidate fails both Revenue and possibly Earnings (Cash Flow?) tests, I would suggest one looks no further for the Perfect Stock.

    If the other tests are all favorable, perhaps Nutrisystems could be labeled a special situation or something else?

    I own three stocks often reviewed by Motley Fool articles: BPI, EBIX and EZPW. I just wish that Motley Fool articles could post a few more Perfect Stocks like these, With All the Warts and all, of course.

  • Report this Comment On July 21, 2011, at 11:12 AM, Blindnomore wrote:

    The perfect stock in this article is now ARNA. Here is why. The link I provide is to the findings of an independent panel picked by the FDA and Arena to go over the data has amassed in it's trials using nearly 8000 participants. If your short Arena you will most likely want to close that position asap. Go see for yourself at:

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1519832, ~/Articles/ArticleHandler.aspx, 10/27/2016 3:16:08 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,203.94 4.61 0.03%
S&P 500 2,137.00 -2.43 -0.11%
NASD 5,226.18 -24.09 -0.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 3:00 PM
NTRI $31.78 Up +0.03 +0.08%
NutriSystem CAPS Rating: *
ARNA $1.58 Down -0.01 -0.63%
Arena Pharmaceutic… CAPS Rating: ***
MED $41.34 Up +0.32 +0.78%
Medifast CAPS Rating: **
OREX $3.00 Down -0.04 -1.28%
Orexigen Therapeut… CAPS Rating: *
VVUS $1.11 Down -0.01 -0.89%
VIVUS CAPS Rating: **
WTW $10.07 Up +0.02 +0.20%
Weight Watchers In… CAPS Rating: **